JointHealth™ express   October 6, 2020

Call for patient input on biosimilar infliximab (Celltrion Healthcare) for rheumatoid arthritis

Do you have rheumatoid arthritis? We need your valuable input

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for biosimilar infliximab for the treatment of rheumatoid arthritis. The originator biologic, or reference product, is infliximab (Remicade®).

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient organizations and groups, like Arthritis Consumer Experts (ACE). Because patient input is vitally important to government decision-making about medications, we would like to gather your views and share them with the CDR.

These are the questions they are asking:
  1. What are the disease-related symptoms and problems that impact the patients' day-to-day life and quality of life? For example, what aspects of their disease are more important to control, how does the disease affect day-to-day life, and are there any activities that the patient is not able to do as a result of the disease?
  2. How well are patients managing their disease with currently available treatments? Examples of the types of information to be included in the answer are:
    • Are patients using or have they ever used the originator biologic (Remicade®) for the treatment of their disease?
    • What therapy are patients using for the treatment of their disease?
    • How effective are current treatments in controlling the common aspects of the disease?
    • Are there needs, experienced by some or many patients, which are not being met by the current treatments? What are these needs?
    • Do current treatments have adverse effects that are more difficult to tolerate than others? What are they?
    • Do patients have difficulty accessing current treatments because of costs, such as costs related to travel and drug administration costs?
    • When offered, how do the patient assistance or support programs impact on the accessibility and effectiveness of the treatment?
  3. How does the disease affect caregivers?
    • What challenges do family and friends who support a patient to manage the disease face?
    • What impact does the treatment have on the caregiver’s daily life, such as emotional/psychological effects, fatigue, stress, and physical challenges?
  4. What are patients’ expectations for the biosimilar?
    • What are the perceived advantages or disadvantages of the biosimilar?
    • What are the aspects of the patients’ disease that it is hoped will be addressed?
    • How might daily life and quality of life for patients, caregivers, and families be different if the new treatment provided desired improvements?
    • What trade-offs do patients, families and caregivers consider when choosing a therapy?
    • If the biosimilar was less expensive than the originator biologic, what would the impact be for patients, caregivers, and families?
  5. Has the patient tried biosimilar infliximab (Celltrion Healthcare)?
    • What were the benefits or disadvantages of biosimilar infliximab?
    • How did the benefits or disadvantages impact the lives of patients, caregivers, and families?
    • Did the patient experience any side effects and were they tolerated? How were the side effects managed?
    • Was the drug easier to use than previous therapies? How so?
If you live with rheumatoid arthritis or care for someone with rheumatoid arthritis, please send us your input by completing this survey or emailing us at by Wednesday, October 14, 2020, so that we may make a submission by the October 16th deadline. Your input will be anonymous.